← Marsh & McLennan Companies overview

Marsh & McLennan Companies vs The Baldwin Insurance Group: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Marsh & McLennan Companies, Inc. (MRSH)

Q3 2026
▲3

Marsh grows on health-cost demand, buybacks, AI push despite falling insurance rates

  • Q2 beat, buybacks and 10% dividend hike Marsh reported 6% revenue growth and 9% higher adjusted EPS, bought back $750 million of stock and raised its dividend 10% for a 17th straight year. Steady profit and cash returned to shareholders support the share price.

    The quarter's results and capital returns are the core new financial facts driving the stock.

  • Health-cost surge lifts benefits consulting demand Marsh's survey projects US employer health costs will jump 8.2% in 2027, the steepest since 2003. Rising costs push employers to seek Marsh's benefits advice, supporting demand for its consulting business and its revenue outlook.

    This is the period's biggest demand driver for Marsh's consulting arm.

  • Falling insurance rates offset by AI and new services Commercial insurance rates fell 6% and property rates 12%, a headwind to brokerage commissions. Marsh is countering with AI tools like Risk Companion and new offerings such as Archer, which add recurring service revenue and broaden its mix.

    It captures the main negative force on pricing and the company's response.

  • Analysts see 2026 earnings up 7.1% Zacks notes rising 2026 earnings estimates, a $5.5 billion capital deployment plan and management consulting growing 13.4% organically, its fastest in over two years. Upward revisions and expected Q3 beat support the stock.

    Analyst estimate momentum and capital plans are a key forward-looking driver.

August 2026
▲3

Marsh grows on health-cost demand, buybacks, AI push despite falling insurance rates

  • Q2 beat, buybacks and 10% dividend hike Marsh reported 6% revenue growth and 9% higher adjusted EPS, bought back $750 million of stock and raised its dividend 10% for a 17th straight year. Steady profit and cash returned to shareholders support the share price.

    The quarter's results and capital returns are the core new financial facts driving the stock.

  • Health-cost surge lifts benefits consulting demand Marsh's survey projects US employer health costs will jump 8.2% in 2027, the steepest since 2003. Rising costs push employers to seek Marsh's benefits advice, supporting demand for its consulting business and its revenue outlook.

    This is the period's biggest demand driver for Marsh's consulting arm.

  • Falling insurance rates offset by AI and new services Commercial insurance rates fell 6% and property rates 12%, a headwind to brokerage commissions. Marsh is countering with AI tools like Risk Companion and new offerings such as Archer, which add recurring service revenue and broaden its mix.

    It captures the main negative force on pricing and the company's response.

  • Analysts see 2026 earnings up 7.1% Zacks notes rising 2026 earnings estimates, a $5.5 billion capital deployment plan and management consulting growing 13.4% organically, its fastest in over two years. Upward revisions and expected Q3 beat support the stock.

    Analyst estimate momentum and capital plans are a key forward-looking driver.

Latest
▲3

Marsh grows on health-cost demand, buybacks, AI push despite falling insurance rates

  • Q2 beat, buybacks and 10% dividend hike Marsh reported 6% revenue growth and 9% higher adjusted EPS, bought back $750 million of stock and raised its dividend 10% for a 17th straight year. Steady profit and cash returned to shareholders support the share price.

    The quarter's results and capital returns are the core new financial facts driving the stock.

  • Health-cost surge lifts benefits consulting demand Marsh's survey projects US employer health costs will jump 8.2% in 2027, the steepest since 2003. Rising costs push employers to seek Marsh's benefits advice, supporting demand for its consulting business and its revenue outlook.

    This is the period's biggest demand driver for Marsh's consulting arm.

  • Falling insurance rates offset by AI and new services Commercial insurance rates fell 6% and property rates 12%, a headwind to brokerage commissions. Marsh is countering with AI tools like Risk Companion and new offerings such as Archer, which add recurring service revenue and broaden its mix.

    It captures the main negative force on pricing and the company's response.

  • Analysts see 2026 earnings up 7.1% Zacks notes rising 2026 earnings estimates, a $5.5 billion capital deployment plan and management consulting growing 13.4% organically, its fastest in over two years. Upward revisions and expected Q3 beat support the stock.

    Analyst estimate momentum and capital plans are a key forward-looking driver.

The Baldwin Insurance Group, Inc. (BWIN)

Q3 2026
▲2

Baldwin to go private in $7.7B cash deal at $32.50 a share

  • Take-private at a big cash premium Sequence Holdings and Michael Dell's family office agreed to buy Baldwin for $7.7 billion, paying $32.50 a share in cash — about an 88% premium to the price before deal talks surfaced. That fixed cash price is why the stock jumped and now trades near $32, close to the offer.

    The take-private is the single event that now sets BWIN's price.

  • Buyers committed, no financing condition The buyers signed a definitive deal with no financing condition, and the board unanimously approved it. Eligible employees can roll part of their stock into the private company. That structure makes the $32.50 payout look more certain, supporting the shares near the offer price.

    Deal certainty is what keeps the stock pinned near the cash offer.

  • Little upside left; closing still needs approvals With shares around $31.89 versus the $32.50 cash offer, almost all the gain is already priced in. Shareholders must still vote and regulators must clear the deal, expected to close in early 2027, so any delay or rejection is the main risk now.

    It is the real counterweight: the easy money has been made and completion risk remains.

  • Solid profit growth, but weak organic sales and a net loss Baldwin entered the deal with revenue up 30% and adjusted EBITDA up 37%, yet organic revenue rose only 2% and it posted a $56 million GAAP net loss. The buyers are paying about 20 times trailing adjusted EBITDA, a full price that reflects these mixed results.

    It explains the operating backdrop behind the price the buyers agreed to pay.

August 2026
▲2

Baldwin to go private in $7.7B cash deal at $32.50 a share

  • Take-private at a big cash premium Sequence Holdings and Michael Dell's family office agreed to buy Baldwin for $7.7 billion, paying $32.50 a share in cash — about an 88% premium to the price before deal talks surfaced. That fixed cash price is why the stock jumped and now trades near $32, close to the offer.

    The take-private is the single event that now sets BWIN's price.

  • Buyers committed, no financing condition The buyers signed a definitive deal with no financing condition, and the board unanimously approved it. Eligible employees can roll part of their stock into the private company. That structure makes the $32.50 payout look more certain, supporting the shares near the offer price.

    Deal certainty is what keeps the stock pinned near the cash offer.

  • Little upside left; closing still needs approvals With shares around $31.89 versus the $32.50 cash offer, almost all the gain is already priced in. Shareholders must still vote and regulators must clear the deal, expected to close in early 2027, so any delay or rejection is the main risk now.

    It is the real counterweight: the easy money has been made and completion risk remains.

  • Solid profit growth, but weak organic sales and a net loss Baldwin entered the deal with revenue up 30% and adjusted EBITDA up 37%, yet organic revenue rose only 2% and it posted a $56 million GAAP net loss. The buyers are paying about 20 times trailing adjusted EBITDA, a full price that reflects these mixed results.

    It explains the operating backdrop behind the price the buyers agreed to pay.

Latest
▲2

Baldwin to go private in $7.7B cash deal at $32.50 a share

  • Take-private at a big cash premium Sequence Holdings and Michael Dell's family office agreed to buy Baldwin for $7.7 billion, paying $32.50 a share in cash — about an 88% premium to the price before deal talks surfaced. That fixed cash price is why the stock jumped and now trades near $32, close to the offer.

    The take-private is the single event that now sets BWIN's price.

  • Buyers committed, no financing condition The buyers signed a definitive deal with no financing condition, and the board unanimously approved it. Eligible employees can roll part of their stock into the private company. That structure makes the $32.50 payout look more certain, supporting the shares near the offer price.

    Deal certainty is what keeps the stock pinned near the cash offer.

  • Little upside left; closing still needs approvals With shares around $31.89 versus the $32.50 cash offer, almost all the gain is already priced in. Shareholders must still vote and regulators must clear the deal, expected to close in early 2027, so any delay or rejection is the main risk now.

    It is the real counterweight: the easy money has been made and completion risk remains.

  • Solid profit growth, but weak organic sales and a net loss Baldwin entered the deal with revenue up 30% and adjusted EBITDA up 37%, yet organic revenue rose only 2% and it posted a $56 million GAAP net loss. The buyers are paying about 20 times trailing adjusted EBITDA, a full price that reflects these mixed results.

    It explains the operating backdrop behind the price the buyers agreed to pay.